Phathom Pharmaceuticals, Inc. (PHAT) Tops Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Phathom Pharmaceuticals (PHAT) PT Raised to $12 at Goldman Sachs
August 8, 2024 4:17 PM EDTGoldman Sachs analyst Paul Choi raised the price target on Phathom Pharmaceuticals (NASDAQ: PHAT) to $12.00 (from $10.00) while maintaining a Neutral rating.
The analyst comments "Topline beat for Voquezna reflects commercial progress though sales remain nominal. PHAT announced its 2Q24 financial results this... More
